期刊文献+

间歇性禁食在裸鼠体内对肝癌进展的影响

Effect of intermittent fasting on hepatocarcinoma progress in nude mice
下载PDF
导出
摘要 为探究间歇性禁食对肝癌进展的影响,以皮下注射肝癌细胞Huh7的BALB/c裸鼠为研究对象,构建肿瘤模型,比较间歇性禁食对肝癌形成及生长、肝脏生理功能及血脂血糖的影响。结果显示:皮下注射Huh7细胞引起的肝癌病变,与对照组相比较,间歇性禁食组小鼠的成瘤率低,且在相同时间段内,间歇性禁食组小鼠形成的肿瘤体积较小;血清学检测结果表明,间歇性禁食组小鼠的肝损伤程度较低。间歇性禁食对肝癌形成具有一定程度的抑制作用,有望成为抑制或减缓肿瘤恶化的有效方法。 To explore the effect of intermittent fasting on the progress of hepatocarcinoma,BALB/c nude mice were injected subcutaneously with Huh7cells to establish the tumor model.Subsequently,the effects of intermittent fasting on hepatocarcinoma formation and growth,physiological function of liver,blood fat and blood glucose were analyzed.The results showed pathological changes of hepatocarcinoma caused by subcutaneous in jection of Huh7.Compared with the control group,tumor formation rate of intermittent fasting mice was low,and in the same time period,tumor size of intermittent fasting mice was small.In addition,the data from serological experiments showed the liver function of intermittent fasting mice had less injury.This study suggested that intermittent fasting could inhibit the formation of hepatocarcinoma,which is expected to be an effective way to inhibit or relieve tumor deterioration.
作者 冯翠 赵瑞波 贾晓渊 孔祥东 陈侃 FENG Cui;ZHAO Ruibo;JIA Xiaoyuan;KONG Xiangdong;CHEN Kan(College of Life Sciences and Medicine,Zhejiang Sci-Tech University,Hangzhou 310018,China;College of Materials and Textiles,Zhejiang Sci-Tech University,Hangzhou 310018,China)
出处 《浙江理工大学学报(自然科学版)》 2019年第6期812-817,共6页 Journal of Zhejiang Sci-Tech University(Natural Sciences)
基金 浙江省自然科学基金项目(LQ19E020010,LY18H160066,18042291-Y)
关键词 间歇性禁食 肝癌 肿瘤形成 HUH7细胞 intermittent fasting hepatocarcinoma tumor formation Huh7cells
  • 相关文献

参考文献2

二级参考文献33

  • 1杨阳,张海波,蒋立新.升高高密度脂蛋白胆固醇药物的相关研究进展[J].中国分子心脏病学杂志,2010,10(6):374-377. 被引量:3
  • 2Kenneth Fearon,Florian Strasser,Stefan D Anker,et al.Definition and classification of cancer cachexia:an international consensus[J].Lancet Oncol,2011,12:489-495.
  • 3Mondello P,Mian M,Aloisi C,et al.Cancer cachexia syndrome:pathogenesis,diagnosis,and new therapeutic options[J].Nutr Cancer,2015,67(1):12-26.
  • 4Wallengren O,Lundholm K,Bosaeus I.Diagnostic criteria of cancer cachexia:relation to quality of life,exercise capacity and survival in unselected palliative care patients[M].Support Care Cancer,2013,21(6):1569-1577.
  • 5Von Haehling S,Anker SD.Treatment of Cachexia:An Overview of Recent Developments[J].J Am Med Dir Assoc,2014,15(12):866-872.
  • 6Radbruch L,Elsner F,Trottenberg P,et al.Clinical practice guidelines on cancer cachexia in advanced cancer patients[J].Aachen:Department of Palliative Medicine/European Palliative Care Research Collaborative,2010.
  • 7Esper DH,Harb WA.The cancer cachexia syndrome:a review of metabolic and clinical manifestations[J].Nutr Clin Pract,2005,20(4):369-376.
  • 8Gullett NP,Hebbar G,Ziegler TR.Update on clinical trials of growth factors and anabolic steroids in cachexia and wasting[J].Am J Clin Nutr,2010,91(4):1143-1147.
  • 9Diament MJ,Peluffo GD,Stillitani I,et al.Inhibition of tumor progression and paraneoplastic syndrome development in a murine lung adenocarcinoma by medroxyprogesterone acetate and indomethacin[J].Cancer Invest,2006,24:126-131.
  • 10Yamashita JI,Ogawa M.Medroxyprogesterone acetate and cancer cachexia:interleukin-6 involvement[J].Breast Cancer,2000,7:130-135.

共引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部